However, other DLBCL cell lines containing the CD79B mutation (OCI-LY3, MD903) [11] were resistant, demonstrating that activating mutations in the BCR pathway do not necessarily predict a response. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.